Comparative efficacy of carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) in newly‐diagnosed …

BA Costa, TA Costa, K Pak, A Patel, N Felix… - American Journal of … - Wiley Online Library
To the Editor: The treatment paradigm of newly-diagnosed multiple myeloma (NDMM) has
undergone a profound change over the past few decades, with induction regimens evolving …
相关文章

Comparative efficacy of carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) in newly-diagnosed …

BA Costa, TA Costa, K Pak, A Patel… - American journal of … - pubmed.ncbi.nlm.nih.gov
In view of the increasing data evaluating carfilzomib-based induction for newly-diagnosed
multiple myeloma (NDMM), we conducted a systematic review and meta-analysis comparing …

Comparative efficacy of carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) in newly-diagnosed …

BA Costa, TA Costa, K Pak, A Patel, N Felix… - American Journal of …, 2024 - europepmc.org
In view of the increasing data evaluating carfilzomib-based induction for newly-diagnosed
multiple myeloma (NDMM), we conducted a systematic review and meta-analysis comparing …